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Abstract: Pioglitazone (PGZ) is an oral anti-hyperglycemic agent, belongs to the class of thiazolidine-
diones, and is used for the treatment of diabetes mellitus type 2. In recent years, its anti-inflammatory
activity has also been demonstrated in the literature for different diseases, including ocular inflam-
matory processes. Additionally, this drug belongs to Class II of the Biopharmaceutical Classification
System, i.e., slightly soluble and highly permeable. The main objective of this study was to validate a
new analytical HPLC-MS/MS method to quantify free-PGZ and PGZ from polymeric NPs to conduct
nanoparticle application studies loaded with this active ingredient to transport it within ocular
tissues. An accurate, sensitive, selective, reproducible and high throughput HPLC-MS/MS method
was validated to quantify PGZ in cornea, sclera, lens, aqueous humor, and vitreous humor. The
chromatographic separation was achieved in 10 min on a Kinetex C18 column. Linear response of
PGZ was observed over the range of 5–100 ng/mL. The recovery of free-PGZ or PGZ from NPs was
in the range of 85–110% in all tissues and levels tested. The intra-day and inter-day precision were
<5% and <10%, respectively. The extracts were shown to be stable in various experimental conditions
in all matrices studied. The range of concentrations covered by this validation is 80–1600 µg/kg of
PGZ in ocular tissues. It is concluded that this method can be applied to quantify PGZ for in vivo
and ex vivo biodistribution studies related to the ocular administration of free-PGZ and PGZ from
nanoparticles.
Keywords: pioglitazone (PGZ); polylactic-co-glycolic acid-polyethylene glycol (PLGA-PEG); nanopar-
ticles (NPs); ocular tissues; validation; HPLC-MS/MS
1. Introduction
Pioglitazone (PGZ) is a hypoglycemic therapeutic drug used in the treatment of type
2 diabetes which increases cell sensitivity to insulin via selective stimulation of the nuclear
receptor peroxisome proliferator-activator receptor gamma (PPARγ) [1,2]. Studies have
shown that the agonist PPARγ receptor is also involved in inflammatory processes [3,4],
and PGZ has been found to be effective as an anti-inflammatory drug in animal models of
paw edema [5] or acute myocardial infarction [6]. Moreover, PGZ reduced the inflammation
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in atherosclerosis [7,8], in skin inflammation processes [9,10], and ocular diseases such as
uveitis [11] or corneal inflammation [12,13].
Other reported properties of PGZ found in the literature range from lung anti-
inflammatory and anti-fibrotic [14], corneal anti-fibrotic [15], corneal neovasculariza-
tion [16] to dry eye disease treatment [17]. In recent years, research has also been conducted
with PGZ for the treatment of Alzheimer’s disease [18–20].
As a result of the chemical structure, PGZ is slightly soluble in water and highly
permeable in membranes [21]. Due to these characteristics, it is very important to find new
vehicles that overcome the solubility problems that restrict its bioavailability when the way
of administration for the treatment is not in the form of oral tablets [22–25].
Nowadays, drug delivery systems that target different organs and tissues are a new
challenge. Polylactic-co-glycolic acid (PLGA) is one of the most studied synthetic polymers
due to its biocompatibility and biodegradability [26], and it has also been approved by the
US Food and Drug Administration (FDA) and the European Medicine Agency (EMA) for
drug delivery systems in humans [27]. This polymer allows the development of very small
particles with narrow polydispersity. Consequently, it has been used to design nanoparticles
(NPs) for biomedical applications as carriers of active ingredients in vaccination, cancer
therapies, skin diseases, ocular and neurological disorders [28–35]. However, PLGA
is a relatively hydrophobic polymer, and once it is in the blood, it is recognized and
phagocyted by macrophages. To avoid this, a modification of its surface using polyethylene
glycol (PEG) could be an alternative. PEG is a biocompatible, hydrophilic, nonionic, and
approved polymer by the FDA for its use in humans. PEGylation is one of the most used
techniques to modify the surface properties of the nanoparticles. In this case, PEGylated
NPs take higher polarity and hydrophilicity avoiding aggregation, opsonization and
phagocytosis, prolonging systemic circulation time, and facilitating its tissue penetration
via interstitial [36].
In ocular therapies, one of the challenges is the effective penetration of the drugs
through the eye’s tissue barriers (e.g., corneal, sclera and conjunctiva) to reach targets and to
sustain them. Normally, when ophthalmic formulations are used, less than 5% of the drug
administered is retained on the ocular surface because of the corneal epithelium barrier
and nasolacrimal duct drainage, which means that it is necessary to instill frequently. One
of the most successful approaches to overcome this inconvenience is the use of colloidal
suspensions of NPs as delivery systems [37,38]. These systems have been described
in the literature, showing the effectiveness for ocular delivery principally in form of
liposomes [39,40] and polymeric NPs [41–43].
In recent years, some studies of our research group have been focused on NPs of
PLGA for the treatment of inflammatory disorders, with different therapeutic targets,
including the main nanosystems for ocular diseases [33,44–46]. The new formulations
improved the biopharmaceutical profile of the drugs. In particular, PGZ-NPs of PLGA-
PEG were formulated for eye treatment and also for delivery to the brain [12,47]. These
nanosystems were optimized, characterized, and their anti-inflammatory activity, as well
as their tolerance, were demonstrated for in vitro, ex vivo, and in vivo animal models.
The presented study aimed to develop and to validate an HPLC-MS/MS method
following the guidelines of the European Medicines Agency (2019) and the U.S. Food
and Drug Administration (2018) for bioanalytical methods validation [48,49] to focus the
analysis on the application of free PGZ (solution) and PGZ from NPs in different ocular
tissues for future research in the treatment of ocular diseases.
2. Materials and Methods
2.1. Chemicals and Reagents
PGZ was purchased from Capot Chemical (Hangzhou, China) and diblock copolymer
PLGA-PEG 5% (50:50) Resomer® was obtained from Evonik Corporation (Birmingham, AL,
USA). Poly(vinyl alcohol) (PVA) Mw 30,000–70,000 87–90% hydrolyzed, dimethylsulfoxide
(DMSO) and formic acid were acquired from Sigma-Aldrich-Merck (Darmstadt, Germany).
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Acetone, acetonitrile and methanol high-performance liquid chromatography (HPLC)
gradient-grade were purchased from ITW Reagents (Barcelona, Spain). All reagents used
were analytical reagents. Ultrapure water (HPLC grade, >18 MΩ·cm at 25 ◦C) was obtained
using a Milli-Q apparatus from Millipore (Milford, CT, USA).
2.2. Chromatographic Conditions
The analysis was carried out using an Agilent 1260 liquid chromatograph (Agilent
Technologies, Santa Clara, CA, USA). A reversed-phase Kinetex C18 column (2.6 µm
particle size, 50 × 2.1 mm) from Phenomenex (Torrance, CA, USA) was used to perform
the chromatographic separation. The gradient between formic acid 0.1% in water (A)
and formic acid 0.1% in acetonitrile (B) was the following (t(min), %B): (0, 10), (4, 74),
(4.5, 90), (6, 90), (6.1, 10), (10, 10). The column temperature was maintained at 35 ◦C. The
optimization of mobile phase and column selection was based on suitability for the mass
detector, effect on the sensitivity of the method and total time required for the analysis.
The flow rate was fixed at 0.6 mL/min and the injection volume at 1 µL.
The detection of PGZ was achieved using a triple quadrupole mass spectrometer 4000
QTRAP (Sciex, Framingham, MA, USA) equipped with a TurboV ion source operating in
positive ion mode with the following settings: capillary voltage +5500 V, nebulizer gas
(N2) 50 (arbitrary units), curtain gas (N2) 25 (arbitrary units), collision gas (N2) medium
(arbitrary scale), drying gas (N2) 30 (arbitrary units) heated to 550 ◦C, declustering potential
(DP) 100 V, entrance potential (EP) 10 V, collision energy (CE) 35 V and collision cell exit
potential (CXP) 12 V.
The use of a triple quadrupole mass spectrometer allowed us to work in multiple
reaction monitoring (MRM) mode. The m/z transition pairs used for quantitation of
PGZ (precursor ion/product ion) were 357.2/134.1 (most sensitive), and 357.2/119.1 for
confirmation. The quadrupoles were set at unit resolution. The analytical data were
processed with the Analyst software version 1.6.2 (Sciex, Framingham, MA, USA).
2.3. Pioglitazone Standards
A stock solution of 1 mg/mL of PGZ was prepared in methanol for subsequent
intermediate, spiking, and working standard solutions. The calibration curve was prepared
at concentrations of 5, 10, 25, 50, 75 and 100 ng/mL in methanol. Glass vials were used to
store the solutions throughout the work.
2.4. Biological Material
Ocular specimens were obtained under veterinary supervision from pigs used in sur-
gical University practices at the Faculty of Medicine, according to the Ethics Committee of
Animals Experimentation at the University of Barcelona. Pigs (male, weight 30–40 kg) were
anesthetized with intramuscular administration of ketamine hydrochloride (3 mg/kg),
xylazine (2.5 mg/kg) and midazolam (0.17 mg/ kg). Once sedated, the Propofol (3 mg/kg)
was administered by the auricular vein, and immediately afterward they were intubated
and maintained under anesthesia inhaled with isoflurane. After chirurgical experimenta-
tion, the animals were euthanized (250 mg/kg of sodium pentobarbital was administered
through the auricular ear vein under deep anesthesia) and the eyes were immediately
extracted and transported to the laboratory in dry ice. Cornea, sclera, lens, aqueous humor
and vitreous humor were excised in the laboratory and kept frozen at −20 ◦C in Eppendorf
tubes. The separation between the retina and choroid was dismissed because both expertise
and a microscope were needed.
2.5. Preparation of Pioglitazone Nanoparticles
PGZ-NPs were obtained by the solvent displacement method described by Fessi et al. [50].
This technique consists of dissolving the polymer and the compound in an organic solvent,
being a successful method to deliver the lipophilic drug. This technique is based on two
phases: the organic and the aqueous phase. Ten mg of PGZ were solubilized in 0.5 mL
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of DMSO and 75 mg of PLGA-PEG were dissolved with 5 mL of acetone. Both organic
solutions were mixed followed by sonication in an ultrasonic bath (100 w) for two minutes.
This organic phase was added drop by drop, gently mixing, into 10 mL of an aqueous
solution of PVA 1.5%. The NPs dispersion was concentrated to 10 mL under reduced
pressure (Vacuubrand PC 2001 Vario, Wertheim, Germany). The PGZ-NPs suspensions
were stable in the fridge for 6 weeks. Parameters such as size, polydispersity index (PDI)
and Zeta Potential (ZP) were evaluated to confirm the stability with a Zetasizer Nano ZS
(Malvern Instruments, Malvern, UK). Additionally, the encapsulation efficiency (EE) was
determined by the indirect method [47].
2.6. Pioglitazone Solutions for Biological Matrix Spiking
The suspension of PGZ-NPs containing about 1 mg/mL of PGZ (2.5) was diluted
in water for spiking into ocular tissues (cornea, sclera, aqueous humor, vitreous humor,
lens). The exact amount of PGZ in the suspension NPs was quantified in order to cal-
culate the accuracy and precision of the method when PGZ-NPs were spiked into the
tissues. The chromatographic conditions for PGZ quantitation in the NPs were adapted
from previous studies: liquid chromatography with reverse phase column C18, eluent
acetonitrile-ammonium acetate buffer with ultraviolet detection at 268 nm [9]. Free-PGZ
solution (1 mg/mL) was diluted in methanol to prepare spiked samples (2.3).
2.7. Extraction Procedure
Lens, aqueous and vitreous humor were vortex-mixed previously. Sclera and cornea
were minced and thoroughly perforated using a needle to help the penetration of the
extraction solution. For cornea, sclera, and lens, the taken weight was about 125 mg; for
aqueous and vitreous humor, the weight was about 250 mg. The samples were weighed
into amber glass vials and were extracted with 2 mL of methanol using an ultrasonic bath
for 30 min. The solution was centrifuged at 10,000 rpm for 10 min at room temperature.
The resultant supernatants were filtered through nylon filters of 0.22 µm and injected into
the HPLC-MS/MS system. The stability of the extracts showed that the supernatants could
be collected and stored at −20 ◦C until use (three months tested).
2.8. Method Validation
The method was validated according to the bioanalytical method validation guidelines
of the EMA and the FDA and considering the acceptance criteria recommended for the
following validation parameters: selectivity–specificity, matrix effect, calibration curve
(response function), limits of quantification and detection, accuracy, precision, recovery,
carry-over, dilution integrity and stability [48,49].
2.8.1. Selectivity and Specificity: Matrix Effect
Blank tissues were analyzed to determine the selectivity and specificity of the method.
Any interference from unwanted tissue components at the elution time of PGZ was evaluated.
The matrix effect is defined as an alteration of the analyte response due to interfering
components in the sample. The effect of tissue components on the ionization of PGZ
was determined by comparison of the response of three replicates of a free-PGZ working
solution prepared in methanol and free-PGZ working solutions prepared in the blank
extract for each tissue. The PGZ concentration was calculated with the calibration curve.
Along with the validation procedure, the matrix effect was also evaluated for accuracy and
precision data.
2.8.2. Recovery
Weighed tissues were spiked with free-PGZ and PGZ-NPs at three levels of concentra-
tion to achieve the final concentrations in the extract of about 10 (low), 20 (medium) and
100 (high) ng/mL, n = 3 each level. As free-PGZ was spiked from small volumes (10–20 µL)
of standard solutions prepared in methanol, to reduce pipetting errors the aliquot added
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was weighed with a minimum precision of 0.1 mg. Samples spiked with the free-PGZ
standard solution were extracted after 60 min waiting time at room temperature and those
spiked with PGZ-NPs were extracted after 3 h waiting time at room temperature to let
them interact with the tissue and better simulate incurred residues. The extracts were kept
at −20 ◦C until HPLC-MS/MS analysis.
2.8.3. Dilution Integrity
The sample dilution effect was also evaluated to ensure that PGZ concentrations be-
yond the upper limit of concentration of the calibration range could be correctly determined
after dilution of the extract with methanol. Three replicates of spiked tissues were used to
investigate the intra-day precision and accuracy of a 50-fold sample dilution. The ocular
tissues were spiked to achieve the final concentration of PGZ in the injected extract of about
50 ng/mL. Both addition of free-PGZ and PGZ-NPs were assayed. This concentration
corresponded to about 2000 µg PGZ/kg for aqueous and vitreous humor, and 4000 µg
PGZ/kg for lens, sclera and cornea.
2.8.4. Calibration Curve
The calibration curve was prepared using six calibration standards defined in Section 2.3.
The chromatographic area of PGZ against the concentration of the calibration standards
was plotted to construct the calibration curve. The linearity of the method was evaluated
by weighted linear regression analysis, with 1/x2 as the weighting factor, using the least-
squares method [51]. The acceptance criteria for the back-calculated standard concentration
were ±15% deviation from the theoretical value. The calibration curve (six standards) was
prepared using fresh standards in each assessment.
2.8.5. Accuracy and Precision
The spiked levels of PGZ concentration corresponded to approximately 160, 320 and
1600 µg/kg for lens, cornea and sclera. For aqueous humor and vitreous humor, the
spiked levels of PGZ concentration corresponded to approximately 80, 160 and 800 µg/kg.
The closeness of mean results determined by the method to the spiked concentration of
the analyte and the repeatability was evaluated in terms of recovery. Three sets of three
different levels of tissues spiked with free-PGZ were prepared and quantified on three
separate days to determine the inter-day and intra-day precision and the accuracy of the
method. Samples spiked with PGZ-NPs were prepared and quantified for accuracy and
intra-day precision (n = 3) at the three levels of concentration.
The acceptance criteria for accuracy of the data should be within ±15% (recovery
85–115%). For the limit of quantitation (LOQ) the accuracy acceptable limit of deviation
is ±20% (recovery 80–120%). The precision around the theoretical value should not cross
15% of the coefficient of variation (CV) and 20% at LOQ [48,49].
2.8.6. Limits of Quantification (LOQ) and Detection (LOD)
The LOQ is defined as the lowest concentration that can be measured with an intra-day
and inter-day precision (expressed as the percentage of the coefficient of variation, CV)
that must not exceed 20%, and accuracy (expressed as the percentage of the deviation from
nominal concentration, bias) that must be within ±20%. The LOQ was evaluated in three
replicates on a single day and three different days for all studied matrices.
The limit of detection (LOD) consists of the lowest concentration whose respective
signal can be dependably distinguished from the background level. The LOD was assessed
by analyzing successive dilutions of blank extract of tissues with added known amounts of
PGZ. See Section 3.2.9 for more details.
2.8.7. Stability Experiments
The obtained extracts from the recovery and precision study were kept at −20 ◦C
till the day of the HPLC-MS/MS analysis because of the availability of the equipment.
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The long-term stability evaluation was deduced from the obtained results of accuracy and
precision studies (three different days). One of the sets was injected three months after the
extraction, the other two sets after 9 and 15 days, respectively.
Extracts of each tissue spiked at approximately the medium level of concentration were
injected to determine the stability of pioglitazone in various predetermined conditions. The
post-preparative stability of the samples was determined after comparison of the response
of immediate injection of the extracted samples to that of the re-injected samples after
keeping them in the refrigerated autosampler for 24 h. The post-preparative stability of the
drug was assessed, taking into account the time that the samples could remain in queue
in the chromatograph and, eventually, any failure of the chromatograph in a 24 h period.
Short-term stability was determined after placing the extracts for eight hours on the bench
top at room temperature. The period for the short-term stability study was determined
based on the possible time spent for a batch sample analysis. The relative stability was
calculated by considering the initial area of PGZ as 100%.
2.9. Bioavailability Experiment: In Vivo
To investigate the ocular bioavailability and disposition of PGZ, pig eyes were treated
with topical administration of 0.05 mL of PGZ-NPs suspension of a concentration of about
1 mg/mL of PGZ. After four hours the pig was euthanized. Cornea, lens, sclera, aqueous
and vitreous humors were processed according to the validated method.
3. Results
3.1. Nanoparticle Preparation
The PGZ-NPs were synthesized by displacement technique, showing a particle size
around 200 ± 2.5 nm, PDI of 0.2 ± 0.03 and a ZP of −15.0 ± 1.3 mV. Moreover, the
percentage of EE was around 92.1 ± 3.2%. These NPs were shown to be stable in the fridge
for six weeks.
3.2. Method Validation
3.2.1. Selectivity and Specificity
The analysis of blank samples (matrix samples processed without the addition of
PGZ) showed no interfering signals in chromatograms of the blank extracts. The retention
time for PGZ was about 3 min and there were no interfering matrix components when
determining PGZ in any of the tissues of the assay. Typical MRM chromatograms of PGZ
found in cornea and PGZ standard (5 ng/mL) are shown in Figures 1 and 2, respectively.
3.2.2. Matrix Effect
Despite HPLC-MS/MS standing out for its high selectivity and specificity, the composi-
tion of the matrix is very important and must be taken into account. The matrix composition
could be responsible for increasing or decreasing the signal of the ions being studied.
It was assessed that the matrix components of the tissues did not change the PGZ
response concerning the analyte in a matrix of methanol as the variation found was less
than ±5% (Table 1). Values shown in Table 1 are the average of three replicates. For all
matrices, the results are in accordance with the acceptance criteria: CV not exceeding 15%
for precision and bias within ±15% for accuracy. The external calibration method could,
therefore, be used.
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Table 1. Matrix effect in the response of PGZ (n = 3).
PGZ Matrix Condition Mean Found (ng/mL) SD CV (%) Variation (%)
Methanol 51.8 0.56 1.07 -
Sclera extract 54.6 1.65 3.02 +5.34
Cornea extract 53.5 1.47 2.75 +3.12
Lens extract 52.2 0.55 1.06 +0.69
Aqueous humor extract 52.5 0.20 0.38 +1.34
Vitreous humor extract 49.0 1.10 2.24 −5.27
3.2.3. Recovery
The concentration of the spiked sample extracts was calculated from the PGZ cal-
ibration curve (Tables 2–4). Average extraction recoveries for PGZ, n = 3, were in the
range 85–110% (bias −15% to +10%). For all matrices, the results are in accordance with
the acceptance criteria: CV not exceeding 15% for precision and bias within ±15% for
accuracy. The method applies to Free-PGZ and PGZ from NPs. Recovery was obtained as
R (%) = ([PGZ] found/[PGZ] added) × 100.
3.2.4. Calibration Curve
The calibration curve was linear in the PGZ concentration range of 5–100 ng/mL with
a correlation coefficient R2 > 0.99. The calibration curve was freshly prepared for each
chromatographic run. The accuracy found of back-calculated concentration during the
different days of analysis was within 91–108% (accepted ±15% in terms of bias) [48,49].
Figure 3 shows a calibration curve obtained during validation experiments.
Table 2. Absolute recovery (values in mean percentages) of Free-PGZ determined at low, medium and high concentration,
and 50-fold diluted sample. Intra-day results (n = 3).
Level of Concentration
in Extract Recovery (%)
ng/mL Lens Cornea Sclera Aqueous Humor Vitreous Humor
10 89.0 ± 1.9 *CV (%) = 2.1
96.9 ± 0.5
CV (%) = 0.5
97.7 ± 3.3
CV (%) = 3.4
92.2 ± 0.4
CV (%) = 0.4
89.5 ± 1.6
CV (%) = 1.7
20 85.0 ± 1.4CV (%) = 1.7
100.9 ± 2.2
CV (%) = 2.2
98.5 ± 2.7
CV (%) = 2.7
91.6 ± 1.2
CV (%) = 1.3
89.4 ± 0.4
CV (%) = 0.4
100 85.2 ± 0.5CV (%) = 0.6
93.9 ± 3.2
CV (%) = 3.4
88.4 ± 2.7
CV (%) = 3.1
86.4 ± 1.1
CV (%) = 1.3
86.7 ± 1.7
CV (%) = 1.9
2500 109.6 ± 3.8CV (%) = 3.5
85.0 ± 0.7
CV (%) = 0.8
88.0 ± 0.4
CV (%) = 0.4
97.2 ±1.8
CV (%) = 1.9
99.6 ± 0.4
CV (%) = 0.4
* Mean ± SD.
Table 3. Absolute recovery (values in mean percentages) of Free-PGZ determined at low, medium and high concentration.
Inter-day accuracy and precision data (n = 9).
Level Concentration
in Extract Recovery (%)
ng/mL Lens Cornea Sclera Aqueous Humor Vitreous Humor
10 93.1 ± 4.9 *CV (%) = 5.2
97.8 ± 1.5
CV (%) = 1.5
89.7 ± 7.9
CV (%) = 8.8
92.3 ± 8.4
CV (%) = 9.1
98.3 ± 6.7
CV (%) = 6.8
20 91.8 ± 5.3CV (%) = 5.8
97.4 ± 3.1
CV (%) = 3.2
89.1 ± 8.2
CV (%) = 9.2
92.5 ± 5.7
CV (%) = 6.2
98.5 ± 6.9
CV (%) = 7.0
100 87.8 ± 2.2CV (%) = 2.4
93.0 ± 6.9
CV (%) = 7.4
85.0 ± 3.1
CV (%) = 3.6
87.7 ± 4.8
CV (%) = 5.4
92.3 ± 4.3
CV (%) = 4.7
* Mean ± SD.
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Table 4. Intra-day accuracy and precision data (n = 3) for tissues spiked with PGZ-NPs: low, medium, high concentration
levels, and 50-fold diluted sample.
Tissue
Nominal Concentration in Extract
Added (ng/mL) Found (ng/mL) SD CV (%) Recovery (%)
Lens
8.4 7.2 0.2 2.7 85.9
17.5 18.9 0.6 3.0 108.0
87.7 90.2 1.9 2.2 102.8
2094 2294.6 79.2 3.5 109.6
Cornea
8.4 7.8 0.3 4.0 93.0
16.8 15.5 0.2 1.1 92.1
84.2 76.0 1.4 1.8 90.2
2094 1779.1 13.6 0.8 85.0
Sclera
8.4 7.8 0.3 3.7 92.0
16.8 16.0 0.4 2.4 94.9
84.2 74.6 0.9 1.3 88.5
2094 1842.8 7.6 0.4 88.0
Aqueous 7.4 6.4 0.3 4.2 87.4
Humor 14.8 12.6 0.2 1.3 85.2
73.8 62.9 0.4 0.7 85.3
1931 2139.0 40.1 1.9 110.8
Vitreous 7.4 7.3 0.4 6.1 99.1
humor 14.8 14.6 0.3 2.0 98.8
73.8 70.7 1.8 2.5 95.8
1937 1925.3 7.2 0.4 99.4
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7.46e + 003 (r = 0.9996)).
3.2.5. ccuracy and Precision
Experi ental concentrations of spiked samples should not deviate more than ±15%
from their nominal concentrations. Intra-day and inter-day accuracies (Tables 2–4) given
by bias (100-Recovery%) varied between −15% for lens and sclera at some added levels to
+10% for the lens at the 50-fold diluted level, but no bias was observed with concentration.
The results shown in Tables 2–4 indicate that the intra-day and inter-day precisions, given
as CV (%), did not exceed 5% and 10%, respectively. The acceptance criteria defined by the
EMA and FDA were fulfilled at the assessed concentration levels.
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3.2.6. Dilution Integrity
The dilution integrity of the samples to demonstrate that a sample dilution procedure,
when required, will not impact the accuracy and precision of the measured concentration
of the analyte, was investigated in all matrices. It was demonstrated that a 50-fold dilution
of a spiked sample can be applied when the concentration of the sample is higher than the
upper limit of the calibration curve (Tables 1 and 3).
In contrast, if the concentration in the extract of real samples was below the lower
limit of the calibration curve, a new calibration curve could be constructed with lower
concentration standards. Minor modifications like increasing the injection volume could be
assayed to get more intensity because it was found that standards of PGZ of 0.05 ng/mL
provided a signal distinguishable from the blank (Figure 4). However, according to inter-
national guidelines, if method conditions were modified, the results should be confirmed
with a partial validation, comprising at least accuracy and precision determination.
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3.2.7. Carry-Over
Carry-over was assessed during method development and validation and it was ob-
served that it was unavoidable. At the beginning of the trial, we had no signal attributable
to PGZ in the blank ionograms. When we started injecting solutions containing PGZ, small
i n signals of ions attributable to this molecule b gan to appear in the blanks, and was
mpossible to remove hem even by cleaning the ionization source of the sp ctrometer.
Methanol was injected at the begin ing of the sequence, after the standards calibration
curve and following the highest levels of spiked samples. Nevertheless, the intensity of
the carry-over signal was practically constant during the batch sequence and with low
variation from one day to another. No concentration effect, therefore, was observed on
the carry-over signal. The carry-over signal in the blank of methanol was found to be
between 1% and 4% of the analyte response at the limit of quantitation level (10 ng/mL).
The extracts of blank tissues showed the same peak intensity as the blank of methanol.
These signal values are in the low ra ge of those accepted in the harmonized guidelines of
validati n methods becau e they recommend that carry over should not exceed 20% of the
LOQ [48,49]. Figure 2 s ows a chromatogram of the carry-over signal and a PGZ standard
of 5 ng/mL. Accuracy and precision data confirmed that the presence of the carry-over
effect did not affect the results.
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3.2.8. Stability
Long-term (three months) sample stability at −20 ◦C was confirmed based on the
obtained results for accuracy (bias ±15%) and precision (CV < 15%), which were found to be
within the acceptable limits. The data for refrigerated stability of the extracts obtained from
in-injector stability (24 h), and short-term stability (8 h) of the extracts at room temperature
indicated that the variation of the response of the extracts was less than ±5% (Figure 5).
The accuracy of back-calculated concentrations in the calibration curve was accepted to
be ±15%, therefore, the variation found in the injection of stability of extracts should
be accepted.
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3.2.9. Limits of Quantification (LOQ) and Detection (LOD)
The LOQ was experimentally accomplished for all tissues and the intra- and inter-day
precision and accuracy results are reported in Tables 2–4. The LOQ was established as
160 µg/kg for sclera, cornea and lens, and 80 µg/kg for aqueous humor and vitreous
humor (10 ng/mL in extract).
The LOD is defined as the concentration that provides a good peak visualization with
the lowest signal-to-noise ratio (S/N) possible [52]. PGZ solutions of 0.05 ng/mL in tissue
extracts were injected and the signal was more than twice in height the carry-over signal
for all the examined tissues and around three times in the area. Taking as background noise
the carry over the peak and the criterion of estimating signals three times higher in area
than the background noise, the LOD was established in the range 0.4–0.8 µg/kg of PGZ in
tissues (Figure 4).
3.3. In Vivo Bioavailability Study
The method proposed herein was used in a pilot study to quantify PGZ in lens, cornea,
sclera, aque us and vitreous h mors, after eye’s administration in form of PGZ-NPs. The
method was sensitive enough to quantify PGZ in the tissues, demonstrating its applicability.
The results presented in Figure 6 show that the maximum concentration was found in the
sclera followed by the cornea. Aqueous humor was the tissue where the concentration
was lowest. According to the validated method, extracts of lens, vitreous hu or, cornea
and sclera had to be diluted to fall into the curve concentr tion range. A dilution 1/20
was ecessary for sclera and cornea extracts, and a dilution of 1/2 for vi reous h mor and
lens extract.
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4. Discussion
PGZ-NPs were successful produced using the displacement technique; this method
provided small particles with good homogeneity and a negative charge of −15.0 mV.
This negative v lue is indicative of the stability of these systems in solution. Moreover,
a hi her percentage of EE was found ( round 92%) for PGZ into the NPs. According
to these physicochemical characteristics, these systems could be suitable for the ocular
application. Previous studies have evaluated PLGA-NPs as ocular drug carriers, and it was
demonstrated that the ocular penetration and permeability of the drugs were improved
when they were encapsulated into the polymer [33,43–46]. The sensitivity of HPLC-UV
methods did not allow the determination of PGZ in real biological samples with a simple
extraction nor probably with preconcentration strategies. Therefore, HPLC-MS was an
alternative technique to consider. Previously published data have shown that HPLC-MS has
been used for PGZ quantitation in liquid biological samples (urine, plasma, serum) [53,54].
However, this i the first alidated method using biological cular tissues. This method
was validated for free-PGZ and PGZ from NPs spiked in ocular tissues, and treated tissues
were also analyzed.
The method was validated in the range 80–1600 µg/Kg of PGZ extracted from the
tissues with good linearity between 5–100 ng/mL of PGZ standards. The extraction
recovery was satisfactory for free-PGZ and PGZ from NPs with recoveries found in the
range of 85–110%. The reproducibility of the method obtained through the inter-day
and intra-day precision was CV < 10% and CV < 5% respectively. Moreover, it was
d monstrated th t a dilution of the extract, if necessary, made it possible to quantify PGZ
with no impact on the accuracy and precision. The LOD an LOQ ac iev d in cornea,
sclera, and lens were on the orders of 0.8 µg/kg and 160 µg/kg respectively. LOD and LOQ
in eye humors were in the orders of 0.4 µg/kg and 80 µg/kg respectively. The sensitivity
was slightly improved compared to data found in the literature [54]. All the experimental
data agree with the guidelines for bioanalytical method validation [48,49].
Significant levels of PGZ were found in eye tissues after 4 h of PGZ-NPs installation
(Figure 6), which means that the formulation permeated and remained in the tissues.
Aqueous humor, which is in contact with the cornea, was the tissue where the amount was
about one order of magnitude lower with respect to the sclera, although PGZ remained.
Vitreous humor, situated behind the scl ra, also presented a good level, indicating that the
formulation permeated throug the sclera. These data are in ccordance with a previous
study in which PGZ accumulated more in sclera than in the cornea [12], probably due to
the hydrophilic characteristics of sclera. This new biodistribution experiment supports
previous results, and this validated method covers the needed concentration range for
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studying different parts of the eye after treatment with PGZ. The formulation developed
perhaps could be useful for the treatment of ocular inflammation with the ability to sustain
PGZ in the tissues and to reach the posterior segment.
Taken together, these results indicate that an accurate, sensitive, selective, reproducible,
and high-throughput HPLC-MS/MS method was developed and fully validated for the
quantitative determination of PGZ from solution and NPs over a wide concentration range
in different eye tissues. This method has the advantage of easy sample preparation, thus
reducing assay time. The sensitivity and selectivity achieved for the detection of PGZ with
respect of HPLC-UV make it suitable for analyzing very low levels of concentration in com-
plex biological matrices. Moreover, HPLC-MS/MS allows the unambiguous identification
of PGZ. The method can be easily applied to in vivo and ex vivo biodistribution studies
related to the ocular administration of PGZ-NPs. Moreover, it opens the applicability to
other types of biological matrices for preclinical or clinical use.
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